| HOME >> BIOLOGY >> TECHNOLOGY |
DETROIT, Sept. 24 /PRNewswire-USNewswire/ -- As the nation combats an alarming rise in chronic diseases, the Pharmaceutical Research and Manufacturers of America (PhRMA) today released a new report on the next generation of medicines in research pipelines that offer hope to millions of patients.
The report found that America's pharmaceutical research and biotechnology companies - including several located in Michigan - are testing a record 633 new biotech medicines.
Today's report was released in Michigan due to the growing prominence of the state's biotech sector in developing and testing cutting-edge medicines. Michigan's life sciences industry has become one of the nation's fastest-growing regions, with 112 new biotechnology companies formed in the state since 2000 - including a number of companies that research and develop new medicines.
"The biotechnology revolution is helping create medicines that use unprecedented technologies, such as nano-sized particles that seek out and kill viruses, ways to actually regenerate healthy muscle to replace damaged heart tissue, and gene therapy," said PhRMA Senior Vice President Ken Johnson. "The impact of this research is felt worldwide. Such critical innovation is creating medicines with the potential to help millions of patients live longer, healthier and more productive lives."
"We are proud of the increasingly important role of Michigan's pharmaceutical biotechnology sector in developing and testing cutting-edge medicines," said Stephen Rapundalo, Ph.D., president of MichBio, the association for Michigan's biosciences industry. "MichBio is committed to providing new hope for patients and to driving the continued growth of Michigan's life sciences industry that makes this possible."
All of the experimental medicines in the report are being tested in human clinical trials or await approval by the U.S. Food and Drug Administration.
The 633 biotechnology medicines being d
'/>"/>
| SOURCE Pharmaceutical Research and Manufacturers of America Copyright©2008 PR Newswire. All rights reserved |